In AML, TP53 mutations or chromosomal aberrations affecting the short arm of chromosome 17 are predominantly found in MDS- or therapy-related acute myeloid leukemia [6, 7] and predict for a higher risk of therapy failure and an adverse survival outcome [1, 8]. Here, TP53 is linked to acute myeloid leukemia.